Search results
Results from the WOW.Com Content Network
Convergence insufficiency. Convergence Insufficiency. Other names. Convergence disorder. Specialty. Ophthalmology, optometry. Convergence insufficiency is a sensory and neuromuscular anomaly of the binocular vision system, characterized by a reduced ability of the eyes to turn towards each other, or sustain convergence .
A prism of power 1 Δ would produce 1 unit of displacement for an object held 100 units from the prism. [2] Thus a prism of 1 Δ would produce 1 cm visible displacement at 100 cm, or 1 metre. This can be represented mathematically as: = where is the amount of prism correction in prism dioptres, and is the angle of deviation of the light.
Maddox rod. The Maddox rod test can be used to subjectively detect and measure a latent, manifest, horizontal or vertical strabismus for near and distance. The test is based on the principle of diplopic projection. [ 1] Dissociation of the deviation is brought about by presenting a red line image to one eye and a white light to the other, while ...
Fixation disparity. Fixation disparity is a tendency of the eyes to drift in the direction of the heterophoria. While the heterophoria refers to a fusion-free vergence state, the fixation disparity refers to a small misalignment of the visual axes when both eyes are open in an observer with normal fusion and binocular vision. [1]
The city’s net cost is $1.85 million, with more than half the total cost covered by energy providers Southern California Edison, the Clean Power Alliance, and the Mobile Source Air Pollution ...
August 5, 2024 at 4:06 PM. WASHINGTON (Reuters) - U.S. Secretary of State Antony Blinken, in a call on Monday with Sudan's army chief Abdel Fattah al-Burhan, reiterated the need for Sudan's ...
The prism cover test ( PCT) is an objective measurement and the gold standard in measuring strabismus, i.e. ocular misalignment, or a deviation of the eye. [1] It is used by ophthalmologists and orthoptists in order to measure the vertical and horizontal deviation and includes both manifest and latent components. [1]
August 9, 2024 at 4:25 PM. (Reuters) - Humacyte said on Friday the U.S. health regulator has extended review of the company's implant that can act as a replacement for an injured or damaged blood ...